ODD

(redirected from Orphan Drug Designation)
AcronymDefinition
ODDOppositional Defiant Disorder
ODDOptical Disk Drive
ODDOrphan Drug Designation (US FDA)
ODDOperational Detachment Delta (US Army)
ODDOne Day Decorating (training program)
ODDOptions Disclosure Document
ODDOracle Dynamic Database
ODDOptical Device Drive
ODDOriginal Delivery Date
ODDOrdered Decision Diagram
ODDOcx and Dll Disclaimer
ODDOne Document Does It All (text encoding initiative)
ODDOld Destroyer (US Navy)
ODDOperational Design Domain
ODDOffice of the Deputy Director
ODDOperator Distance Dialing
ODDOntario Diabetes Database
ODDOffice Dependent Data
ODDOcean Disposal Database
ODDOldest Dear Daughter
ODDOgden Data Device (data transfer cartridge interface)
ODDOff-Board Deception Device
ODDOutline Dimensional Drawing
ODDOn-Dock Delivery (shipping)
ODDOpportunity Description Document
ODDObservatory Description Document (US NASA)
ODDObserved Defect Density
ODDObjective Digitized Division
ODDOutside Designed and Developed
References in periodicals archive ?
Food and Drug Administration , FDA, has granted Orphan Drug Designation to NERLYNX, neratinib, for the treatment of breast cancer patients with brain metastases.
M2 PHARMA-September 2, 2019-US FDA grants orphan drug designation to CARsgen Therapeutics' multiple myeloma therapy
Akari announced Friday that its lead investigational asset nomacopan, which is currently being evaluated for four indications, has been granted orphan drug designation, or ODD, for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, or HSCT-TMA.
M2 EQUITYBITES-July 22, 2019-Aridis Pharmaceuticals' AR-501 receives Orphan Drug Designation
Global Banking News-February 13, 2019-Calliditas Therapeutics wins US FDA orphan drug designation for primary biliary cholangitis
NORDIC BUSINESS REPORT-October 25, 2018-Hansa Medical announces receipt of positive opinion for Orphan Drug Designation in the EU for Imlifidase for anti-GBM disease
Trovagene, Inc.'s PCM-075 for the treatment of acute myeloid leukemia (AML) was granted an orphan drug designation by the FDA.
Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADCT-402 for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma.
23, 2014--BioLineRx (BLRX) has received notice from the FDA confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for acute myeloid leukemia (AML).
23, 2014 -- BioLineRx (BLRX) has received notice from the FDA confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for acute
Orphan drug designation by the FDA is granted upon recognition that the prevalence of the US target patient population is 200,000 or less.
The EMEA grants orphan drug designation to medicinal products based upon several criteria: the life-threatening and debilitating nature of the condition; the medical plausibility of the proposed orphan indication; a prevalence in Europe of less than 5 cases for each 10,000 of population; and the lack of a satisfactory method of diagnosis, prevention or treatment or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition.